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Abstract: Several recent, large-scale studies have provided valuable insights into patient
perspectives on postmenopausal vulvovaginal health. Symptoms of vulvovaginal atrophy, which
include dryness, irritation, itching, dysuria, and dyspareunia, can adversely affect interpersonal
relationships, quality of life, and sexual function. While approximately half of postmenopausal
women report these symptoms, far fewer seek treatment, often because they are uninformed about
hypoestrogenic postmenopausal vulvovaginal changes and the availability of safe, effective,
and well-tolerated treatments, particularly local vaginal estrogen therapy. Because women
hesitate to seek help for symptoms, a proactive approach to conversations about vulvovaginal
discomfort would improve diagnosis and treatment.
Keywords: health care professional, hypoactive sexual desire disorder, local vaginal estrogen
therapy, quality of life, urinary tract infection, vulvovaginal atrophy

Introduction
The current life expectancy for American women is greater than 80 years and continues
to increase.1 At the time of the most recent census (2010), 53 million women aged
50 years and older were living in the United States.2 Based on the average age of
menopause in this population (50.5 years),3 and based on increasing life expectancy,
most of these women may expect to live almost 40% of their lives after menopause.
Therefore, while some may view menopause as an end-of-life event, it is in fact a
midlife event.
Menopause is commonly associated with somatic symptoms, including hot flashes,
night sweats, and fatigue, but women are less frequently aware of menopause-related
vulvovaginal symptoms, including vulvovaginal dryness, recurrent urinary tract
infections (UTIs), and dyspareunia.4–8 These symptoms are often associated with
vulvovaginal atrophy (VVA), a condition that results from decreased estrogen in the
vulvovaginal tissues.9 VVA can be diagnosed based on patient-reported symptoms and
a physical examination.10,11
Symptomatic VVA, which can include an inflammatory reaction to atrophic changes
known as atrophic vaginitis, can range in severity from bothersome to debilitating.
First-line therapies recommended by the North American Menopause Society include
vaginal moisturizers, continued sexual activity, and lubricants.12 Lubricants are temporary in their action and are used immediately before and during sexual activity to
decrease tissue irritation due to friction. In contrast, vaginal moisturizers are applied
internally at regular intervals, are longer-acting, and can decrease vaginal dryness
and lower vaginal pH.13,14 These agents do not restore normal vaginal anatomy and in
International Journal of Women’s Health 2013:5 437–447
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some patients may be insufficient or inadequate to resolve
symptoms, because they do not treat their underlying cause:
the hypoestrogenic vaginal environment. When symptoms
persist after first-line therapies are employed, the two primary
goals of management are to alleviate symptoms and to reverse
atrophic anatomical changes. Vaginal local estrogen therapy
(LET) is considered effective and well tolerated for the treatment of moderate to severe symptomatic VVA;12 because
of minimal systemic absorption of LET, local application is
presently recommended over systemic estrogen therapy when
VVA is the sole indication.12 The cellular and physiological
changes that characterize VVA and the results of clinical
trials investigating various treatments have been reviewed
elsewhere.9,12,15
The aim of this review is to summarize findings from
several recent survey-based studies that have provided
profound insight into women’s experiences, opinions, and
preferences regarding postmenopausal vulvovaginal health.
Increased awareness of these patient perspectives among
health care providers (HCPs) may help improve the diagnosis
and treatment of VVA.

Methods
To locate recent and relevant surveys, a PubMed search was
performed using the search term “postmenopausal women
vaginal survey” and was restricted to English-language
articles in the date range January 1, 2007, to April 1, 2012.
Using the specified search criteria, 107 articles were located.
After eliminating trials, studies that did not use surveys,
studies that surveyed less than 1000 women, as well as
studies that assessed data collected before 2002, a total
of seven studies of women in North America and Europe
remained (Table 1).5–8,16–18 Because the symptoms of VVA
are most prevalent in women who have reached menopause,
this review focuses on the postmenopausal population.
However, relevant data from perimenopausal women have
been presented alongside data from postmenopausal women
for comparison when both populations were addressed in a
single survey. Though this review will emphasize insights
learned from these seven key surveys, other recent surveys
and key studies on vaginal atrophy that were either cited
within the seven key survey publications and/or that were
well known and widely accepted by experts in the field were
also considered to complement, elaborate on, and amplify
these important findings.
For the purposes of this review, VVA is a clinical diagnosis that is made based on an overall impression of symptoms
and visual inspection of the vulvovaginal anatomy, with or
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without testing for confirmatory objective parameters such
as pH or histology. Because all of the key studies considered
in this review focused on self-reported experiences and perceptions, it cannot necessarily be concluded that all of the
women reporting symptoms of VVA would actually receive
that diagnosis from a clinician.

Prevalence of vulvovaginal symptoms
In the seven key studies,5,7,8,16–18 vulvovaginal symptoms were
described slightly differently, but the prevalence of symptoms was consistently about 50% (Table 1). VVA does not
result in symptomatology such as discomfort or pain in all
women. Gass et al11 found that more than two-thirds (69%)
of women participating in the hormone therapy trials of the
Women’s Health Initiative had physical evidence of VVA
upon clinical examination at enrollment; only 10% of the same
population, however, reported moderate to severe vaginal
or genital dryness. This study was unique in that it reported
the prevalence of symptoms (ie, vaginal or genital dryness
and irritation) and the investigator’s clinical impression of
atrophy. While many women exhibited signs of VVA (eg, loss
of adipose tissue in external genitalia; thinning of pubic hair;
atrophic, smooth, pale, or friable vagina; or friable cervix flush
with the vaginal vault), not all were symptomatic.11

Vulvovaginal discomfort
and its effects on women
Perceived severity of vulvovaginal
symptoms
The discomfort associated with VVA can have a significant
impact on health and overall quality of life (QoL). The VIVA
(Vaginal Health: Insights, Views, and Attitudes) study, 8
which covered the broadest range of countries among the
seven key surveys, reported the prevalence of individual
symptoms among 1578 women with vaginal discomfort as
follows: vaginal dryness, 83%; pain during intercourse, 42%;
involuntary urination, 30%; soreness, 27%; itching, 26%;
burning, 14%; and pain when touching the vagina, 11%. In
the same study, most women with discomfort (62%) reported
the severity of these symptoms as moderate or severe. Santoro
and Komi5 found vaginal dryness and sexual pain to be
moderately or very bothersome in 42% of postmenopausal
women who were not currently taking estrogen. Another
study corroborated these findings, with 38% of postmenopausal women reporting that their long-term vaginal dryness
was a significant problem; these women rated the problem 5,
6, or 7 on a Likert scale, with responses ranging from 1 (not
a problem) to 7 (a very significant problem).19
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3520 women aged 55–65 years in
Canada (500), Denmark (500), Finland (500),
Norway (520), the United Kingdom (500),
and the United States (500)

4264 women aged 55–65 years in
Canada (1016), Finland (606), Sweden (604),
the United Kingdom (1008), and the
United States (1012); 98% postmenopausal

2290 postmenopausal women aged
45 to 89 years in the United States

1480 sexually active postmenopausal
women aged 40–65 years in the
United States

2547 peri- or postmenopausal
women (self-classified)

1026, 1072, and 1002 women in three
separate surveys (proportions of pre-,
peri-, or postmenopausal respondents
varied by survey)

1006 postmenopausal women
(with subanalysis of 255 women
who reported pain during sexual
intercourse) and 602 HCPs who
treat postmenopausal women

Vaginal Health: Insight,
Views, and Attitudes
(VIVA)8

Women’s Voices
in the Menopause7

Santoro and Komi5

Levine et al18

Cumming et al16

Cumming et al17

REvealing Vaginal
Effects At mid-Life
(REVEAL) survey6

Phone survey of patients
and online survey of HCPs

Three voluntary, online,
convenient open surveys on
www.menopausematters.co.uk

Voluntary, online,
convenient open survey on
www.menopausematters.co.uk

Online survey
(Internet access provided
to those who lacked it)

Online survey
(Internet access provided
to those who lacked it)

Online survey

Online survey

Design

Note: aPrevalence is reported for postmenopausal women only in surveys that also assessed pre- or perimenopausal women.
Abbreviation: HCP, health care provider.

Respondents

Survey-based study

Table 1 Key survey-based studies

Vaginal dryness (including itching and burning);
vulvar/vaginal pain; incontinence of urine, gas,
or bowels; vaginal infections; loss of sexual
interest or desire; difficulty with lubrication
and arousal; physical discomfort or pain inside
the vagina during sexual activity; difficulty
reaching climax or ability to feel sensation;
physical discomfort or pain on the outer
genitals during sexual activity

Vaginal discomfort

Dyspareunia secondary to vaginal dryness

Vaginal dryness, vaginal itching, vaginal irritation,
pain on urination, vaginal pain associated
with sexual activity, or vaginal bleeding
associated with sexual activity, if experienced
at least once within the prior 4 weeks

Vaginal discomfort, such as dryness, pain,
irritation, itching, or similar symptoms
(currently or in the past)

Vaginal discomfort (dryness, smarting pain,
itching, involuntary urination or pain
in the vagina in connection with touching
and/or intercourse)

Vaginal discomfort (dryness, itching, burning
or soreness in the vagina, involuntary
urination, or vaginal pain in connection
with touching and/or intercourse)

Vulvovaginal symptoms considered

47% vaginal dryness, 10% vulvar/vaginal
pain, 28% incontinence, 7% vaginal
infections, 45% loss of sexual interest,
38% difficulty with lubrication and arousal,
22% physical discomfort or pain inside the
vagina during sexual activity, 25% difficulty
reaching climax or ability to feel sensation,
10% physical discomfort or pain on the
outer genitals during sexual activity

63% in the total sample

56% in the total sample

57% in the United States

45% in the United States

39% in total sample; 43% in the
United States

45% in total sample; 51% in the
United States

Prevalencea
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Effect of vulvovaginal discomfort on QoL
Vulvovaginal symptoms can also affect aspects of women’s
lives beyond physical health. In the Women’s Voices in the
Menopause study, about half (52%) of the respondents
reported at least some degree of negative impact, including
negative consequences for their sex life (40%), self-esteem
(17%), marriage/relationship (13%), and social life (7%),
although 38% reported that their discomfort had not affected
them much.7 Many women also reported that vaginal discomfort made them “feel old” (32%) and gave them a lower QoL
(14%).7 In another study, postmenopausal women agreed that
long-term VVA symptoms adversely affected their sexual
interest (59%), intimacy and relationship with a partner
(55%), mood (42%), and self-esteem (34%).19 Additionally, a
study by Cumming et al17 found that many women have tried
to hide their vaginal dryness/discomfort from their partner
(61% of peri- and postmenopausal women) and have made
excuses to avoid intercourse because of their symptoms (42%
of peri- and postmenopausal women). Respondents also
reported that vaginal dryness/discomfort had affected their
confidence (62% of peri- and postmenopausal women).17

Association of VVA with sexual dysfunction
Vulvovaginal symptoms may contribute to sexual problems
and distress in postmenopausal women. Sexual desire has
been found to decrease as women move through the menopausal transition, partially as a result of declining testosterone
levels.20,21 Levine et al18 found that postmenopausal sexually
active women with sexual dysfunction, as defined using the
Arizona Sexual Experiences Scale questionnaire, were nearly
four times more likely to have symptoms of VVA than those
without sexual dysfunction.22 Also, the co-occurrence of
sexual dysfunction and its separate domains and VVA in this
analysis population was high; for women with VVA, 40%
also reported overall sexual dysfunction, 24% lack of desire,
34% arousal difficulties, and 19% orgasm difficulties.22 These
results are complemented by a separate large study of adult
women (Prevalence of Female Sexual Problems Associated with Distress and Determinants of Treatment Seeking;
PRESIDE), which found that the prevalence of distressing
sexual problems, as measured by the Female Sexual Distress
Scale,23 peaked at 14.8% in middle-aged women aged 45 to 64
years compared with women who were younger (aged 18–44
years, 10.8%) or older (aged $65 years, 8.9%).24
In a second study by Cumming et al,16 more than onethird (38%) of perimenopausal women and more than half
(56%) of postmenopausal women reported dyspareunia
secondary to vaginal dryness. Most of these women (78%
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and 87% in the perimenopausal and postmenopausal groups,
respectively) considered dyspareunia to be a factor in their
loss of libido.16 In another study, difficulty with lubrication
was cited by 39% of women aged 57 to 85 years.25 The survey
by Cumming et al16 also screened peri- and postmenopausal
respondents for hypoactive sexual desire disorder (HSDD)
using the Brief Profile of Female Sexual Function26 and found
that respondents screening positive for HSDD overwhelmingly felt that vaginal dryness was a factor in their reduced
libido (90% of respondents).16 Likewise, a study of Italian
women in surgical menopause found that vaginal dryness
was significantly more reported by women with a decline of
sexual desire than in those without a decline in desire (63.2%
versus 30.2%; P = 0.001).27 In the Study of Women’s Health
Across the Nation, women reporting vaginal dryness were
more likely to report dyspareunia and lower arousal.20
Although many studies published over the last 30 years
have shown that the frequency of sexual intercourse declines
with age,28 a considerable proportion of postmenopausal
women are sexually active.12,16 In examining the baseline
characteristics of women participating in the hormone therapy
trials of the Women’s Health Initiative, Gass et al11 found that
about 61% of women aged 50 to 59 years were sexually active,
followed by 45% of women aged 60 to 69 years and 28% of
women aged 70 to 79 years. Nearly two-thirds (63%) of these
women were satisfied with their sexual activity at the time of
the survey, but of those dissatisfied, the majority (57%) would
prefer more sexual activity. Women with clinically evident
VVA were more likely to report sexual inactivity.11

Tolerating painful sex as a result of VVA
Many postmenopausal women continue to have sex, even
though it is painful. In the REvealing Vaginal Effects At midLife (REVEAL) study, one-quarter of women reported that
they experienced dyspareunia at least sometimes.6 Of this
dyspareunia subgroup, 72% engaged in sexual intercourse at
least once a month and 34% at least once a week, despite the
pain they were experiencing. Remarkably, 80% of the dyspareunia subgroup reported that they had learned to live with the
vulvar and vaginal symptoms of menopause, such as dryness,
as a normal part of getting older (compared with 51% of all
respondents); 30% of women who experience dyspareunia
said that the pain required interruption or discontinuance
of sexual activity.6 Also in the REVEAL study, 56% of the
dyspareunia subgroup said they were less sexually active as a
result of the pain, while 6% said the pain prevented any attempt
at sexual activity.6 The Study of Women’s Health Across the
Nation reported comparable frequency of intercourse between
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premenopausal women and early perimenopausal women who
reported more pain with intercourse.29 Therefore, it appears
that while some women tolerate painful sex, others may reduce
their frequency of sexual activity or discontinue sexual activity
entirely. In each case, a clinical need is evident.

Urinary symptoms associated with VVA
VVA may also be associated with lower urinary tract symptoms, such as dysuria, urgency, frequency, nocturia, incontinence, and recurrent UTIs. In any given year, about 8% of
postmenopausal women may have an episode of UTI, and
about 4% may have two or more episodes.30 Evidence suggests that LET, but not systemic estrogen therapy, may prevent urinary infections and improve symptoms,31,32 including
incontinence, frequency, nocturia, and urgency.33 Although
this review focuses primarily on the vulvovaginal symptoms
of VVA, urinary symptoms also have a high prevalence in
older women and may have negative effects on QoL and
sexual activity.34 The PRESIDE study,35 for example, found
a correlation between distressing sexual problems in women
and urinary incontinence. Treating vulvovaginal symptoms
with LET may address urinary complaints as well.36

Lack of understanding
of vulvovaginal health
Many postmenopausal women are uninformed about midlife
vulvovaginal health and its importance. In one study, 87%
of postmenopausal women agreed with the statement, “My
sexual health is important to me,”6 and in another, 84% of
peri- and postmenopausal women answered “yes” to “Is an
active sex life important?”16 So while most women value the
importance of sex and sexual health, there is still a substantial
minority that does not. In the REVEAL survey, only 9% of
postmenopausal women disagreed with the statement, but
this relatively small percentage potentially corresponds to
4.5 million women (based on an estimated 50 million postmenopausal women in the United States).6 These women
likely have a variety of reasons for deprioritizing their sexual
health, including the lack of a partner, other health concerns,
or avoidance of sex because of vulvovaginal discomfort.
However, women may benefit from receiving basic information about the potential advantages of achieving or maintaining sexual health in their peri- and postmenopausal years.
The VIVA study also investigated women’s knowledge of
vulvovaginal health issues.8 Many women (42%) with vaginal
discomfort realized that their condition was a symptom of
menopause, although few (4%) were able to attribute “dryness, itching, burning or soreness in the vagina, or pain during
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intercourse” to “vaginal atrophy.”8 More than one-third (37%)
recognized vaginal discomfort as a chronic condition, but 45%
did not know if it was chronic or acute; 18% thought it was
an acute condition, despite the fact that 75% of women in the
study had experienced symptoms for at least a year.8 In a separate study,19 postmenopausal women with vaginal discomfort
were asked if they would be more likely to seek treatment if
they knew it was a treatable medical condition called “vaginal atrophy” that could cause urogenital complications if left
untreated. Nearly half of the women (44%) reported that they
would be “very likely” to seek treatment.19 These responses
highlight the importance of discussing the root cause of VVA
(estrogen deficiency) with postmenopausal women.

Underdiagnosis and undertreatment
of VVA
Although many women experience vulvovaginal symptoms
with menopause, they often do not seek medical help.7,8,16
Approximately one-third (32%) of the symptomatic respondents in the VIVA study, for example, had never seen an HCP
for the treatment of vaginal discomfort and 28% waited for
more than 1 year,8 suggesting that VVA is an underdiagnosed
and undertreated condition among postmenopausal women.
Because none of the key surveys asked if a physician had
formally diagnosed symptomatic patients with VVA, the true
rate of diagnosis in these populations is not known and cannot be directly compared with the proportion of women with
symptoms and the proportion of women receiving treatment.
There is, however, a clear discrepancy between the reported
incidence of symptoms (see Table 1) and the reported incidence of treatment, suggesting a need for improved diagnosis
and management of VVA.
In the VIVA study, more women with vaginal discomfort
used over-the-counter lubricating products, including gels
and creams (49%), compared with prescription hormonal
oral tablets and patches (22%), vaginal hormone creams
(13%), vaginal hormone tablets (12%), and vaginal hormone
rings (1%).8 Additionally, 22% of women with vaginal discomfort had not tried any of the treatments mentioned in
the survey; these included those just mentioned as well as
vaginal hormone suppositories and mineral/vitamin supplements (neither of which is approved in the United States for
treating VVA). In Women’s Voices in the Menopause, 63% of
women had never been prescribed any treatment for vaginal
discomfort as a result of menopause, while 19% had been
prescribed treatment in the past and only 17% were currently
undergoing treatment.7 The number of women treated with
prescription (or hormone-based) therapy for vulvovaginal
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discomfort varied by country,7,8 with women in the United
States, Canada, and the United Kingdom being treated less
frequently than women in Finland and Sweden.7
In a UK-based survey, Cumming et al16 reported that only
28% of perimenopausal women and 46% of postmenopausal
women who were experiencing dyspareunia secondary
to vaginal dryness and who believed this to be a factor in
their loss of libido discussed the issue with their HCP. Of
those who had a discussion, only 36% of perimenopausal
respondents and 55% of postmenopausal respondents were
on treatment. Among women with HSDD based on their
answers to the Brief Profile of Female Sexual Function,26
40% had discussed dryness with an HCP and of those only
51% were on treatment.16 While the self-selecting nature of
the sample may have introduced some bias, the results of this
study exemplify how women who are candidates for therapy
are missed at the diagnosis and treatment stages.16
Women who seek treatment for vulvovaginal discomfort
are clearly bothered by their condition, and with treatment,
many women report improvements in their everyday life, sex
life, QoL, and their relationships.7 Women who have been diagnosed with VVA should be encouraged to begin managing their
condition with appropriate treatment, following the guidelines
of the North American Menopause Society, the International
Menopause Society, and the Endocrine Society.12,37,38

Lack of awareness of treatment
options for VVA
Many postmenopausal women are unaware of the recommended treatment options, which may include LET, for vulvovaginal discomfort.7,8 In Women’s Voices in the Menopause,
42% of women did not realize that local treatment was available for vaginal discomfort related to menopause.7 Awareness
was country-specific, with those in the United States having
the greatest lack of awareness (51%) and those in Finland
having the least lack of awareness (10%). VIVA reported that
most women (60%) were aware of over-the-counter options,
such as lubricating gels and creams, although fewer were
aware of prescription therapies.8 Among all categories of
prescription therapies, women were most aware of hormonal
oral tablets and patches (45%), which may be recommended
by some HCPs when there is an additional indication for
systemic therapy, such as the relief of moderate to severe
vasomotor symptoms due to menopause or the prevention of
postmenopausal osteoporosis.39 Awareness of local hormone
therapies, such as vaginal hormone creams (41%), vaginal
hormone tablets (23%), and vaginal hormone rings (12%),
was lower than awareness of oral tablets and patches.39 In
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a separate study, 67% of women said that they did not have
enough information to make an informed choice about whether
or not to start hormone therapy (therapy was not separated into
local or systemic).17 These results suggest that there is a need
to increase awareness of recommended treatment options for
vulvovaginal discomfort among postmenopausal women.
Although about two-thirds of women who are prescribed
hormonal treatment are likely to report positive effects,7
many women are concerned about safety issues.8 The VIVA
study investigated specific concerns about systemic and local
hormone therapy separately.8 The primary concerns about
systemic therapy, including both oral tablets and patches,
were an increased risk of breast cancer (a concern reported
by 53% of women) and an increased risk of developing a
stroke or blood clot (a concern reported by 46% of women).8
These concerns were also expressed regarding LET, although
to a lesser extent: 27% of women were concerned about an
increased risk of breast cancer, whereas 24% were concerned
about an increased risk of developing a stroke or blood clot.8
Strikingly, nearly half (46%) of the women surveyed in VIVA
did not know what perceptions (positive or negative) to
associate with LET, illustrating a need for patient education.
Women do not clearly understand the differences in the risks
and benefits associated with local versus systemic therapy.12,39
Interestingly, 30% of women asserted that they would not consider LET, even if they knew it was effective and capable of
maintaining normal hormone levels.8 However, 49% of women
would be willing to try it and 20% were undecided,8 indicating
that the majority of women, although they may be misinformed
about LET, are receptive to additional information.

Sources of information about
vulvovaginal health
When women in the VIVA study were asked what sources
they had used or would use to understand vulvovaginal
symptoms and/or treatment options, half cited their primary
care doctor (50% overall; 49% United States) or their gynecologist (46% overall; 56% United States).8 Approximately
30% of women cited medical websites, women’s health
websites, or menopause websites; 19% printed information
in their doctor’s office; 15% magazines; and 14% friends.
This information from non-HCP sources, such as the Internet
and other women, may not be accurate or complete.
The PRESIDE study found that women who formally
sought medical help for distressing sexual problems were
generally younger than women who sought no help or who only
sought help anonymously from printed material, television,
radio, or Internet sources.35 Among women who formally
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sought medical help, younger women (aged ,65 years) more
often initiated a discussion with their HCP than older women
(aged $65 years), and older women spoke with a primary
care physician (54%) more often than with a gynecologist
(30%).35 Less than half of women (44%) responding to the
international VIVA study felt that there is enough information
available about the symptoms and treatment of vulvovaginal
discomfort.8 Finland was an outlier in this regard, with 76%
of women reporting that enough information was available,
compared with 37% to 42% in other countries.8

Unwillingness of patients and HCPs
to discuss sexual health
Many postmenopausal women and their HCPs hesitate to
discuss in an open conversation sexual health in general
and vulvovaginal health, specifically; this presents a major
challenge for diagnosing and managing VVA (see the section
titled “Underdiagnosis and undertreatment of VVA”).

Patients’ main concerns
Only 38% of the women surveyed in REVEAL (a US-based
study) had spoken to an HCP about their sexual health in the
past year.6 Remarkably, some respondents (41%) had not talked
to anyone about their sexual health in the past year, even with
their partners or friends.6 Consistent with the data from PRESIDE, this subset increased with age: 29% for women aged
45 to 49 years, 35% for women aged 50 to 54 years, 42% for

women aged 55 to 59 years, and 49% for women aged 60 to 65
years.6 About half (47%) of the respondents in REVEAL agreed
that it is still taboo in society for postmenopausal women to
acknowledge experiencing vulvovaginal symptoms.6
When asked why sexual or vulvovaginal health topics are
not discussed, women typically provide a reason that falls into
one of three major categories: (1) embarrassment; (2) the belief
that nothing can be done; and (3) the belief that the topic is not
appropriate to discuss with an HCP (Table 2). Other reasons
include thinking that the HCP is too busy,6 thinking that the
HCP might be embarrassed,6 or wishing someone else (such as
an HCP) would initiate the conversation.7 The degree to which
these reasons are cited varies by country, with women in the
United States reporting more embarrassment than women in
Canada, Sweden, Finland, or the United Kingdom.7
Additionally, in a study of both men and women aged 57
to 85 years, 38% of men had discussed sex with a physician
since age 50 years, while only 22% of women had done so.25
This discrepancy may result at least partially from societal
constraints, which were explored in the REVEAL study.6 Most
respondents (ie, postmenopausal women aged 55–65 years)
agreed that society constrains the sexual expression of women
their age more than that of men their age (75%), that society is
more accepting of discussing men’s physical sexual problems
than women’s (73%), and that society would prefer to believe
that women their age do not have sex (53% of all respondents;
60% of respondents aged 60–65 years).

Table 2 Self-reported reasons for not discussing vulvovaginal health or dyspareunia with HCP
Reason

Language used in survey

Rate among respondents

Reference

Embarrassment

“It makes me uncomfortable/
embarrassed.”

47% of those with vaginal discomfort

Women’s Voices
in the Menopause7

“I am embarrassed.”

39% of those who have not talked
to an HCP about dyspareunia

REVEAL6

Embarrassed about sexual
problems23

59% of women who did not seek help
were at least moderately embarrassed

PRESIDE35

“It’s just part of growing older.”

39% of those with vaginal discomfort

Women’s Voices
in the Menopause7

“There is nothing than can be
done medically to help me.”

26% of those who have not talked
to an HCP about dyspareunia

REVEAL6

“I do not think other people want
to hear about my vaginal problems.”

59% of those with vaginal discomfort

Women’s Voices
in the Menopause7

“It is private and does not
concern others.”

41% of those with vaginal discomfort

Women’s Voices
in the Menopause7

“It is not an appropriate discussion
to have with an HCP.”

23% of those who have not talked
to an HCP about dyspareunia

REVEAL6

Belief that nothing
can be done

Belief that it is an
inappropriate topic
to discuss with an HCP

Abbreviations: HCP, health care provider; REVEAL, Revealing Vaginal Effects at Midlife study; PRESIDE, Prevalence of Female Sexual Problems Associated with Distress
and Determinants of Treatment Seeking study.
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Patients waiting to report symptoms
In the VIVA study, nearly half (47%) of women who eventually saw an HCP about their symptoms waited more than
6 months, whereas 28% waited more than 1 year and 15%
waited more than 2 years.8 Similarly, the Women’s Voices
in the Menopause study found that 25% of women (32%
of women in the United States) who had been prescribed
treatment for their vulvovaginal symptoms had experienced
symptoms for at least 1 year, while 5% to 11% of women
(depending on country, 11% in the United States) had waited
at least 3 years.7 Some of these women may have simply
been waiting for an HCP to initiate a conversation about
vulvovaginal symptoms or sexual health.7 Others may believe
that such changes would resolve or that they are a normal
part of aging.38

Patient preferences with terminology
When discussing vulvovaginal symptoms and VVA with
patients, HCPs should be mindful that women are generally
not familiar or comfortable with the term “vaginal atrophy.”
In the VIVA study, about one-third (32%) of women felt
that the term “vaginal dryness” was appropriate to describe
“dryness, itching, burning, or soreness in the vagina or pain
during intercourse,” whereas only 11% preferred the term
“vaginal discomfort.”8 Very few women considered the terms
“poor vaginal health” (2%), “vaginal dysfunction” (2%), or
“vaginal atrophy” (2%) to be suitable.8 These preferences
may be helpful to keep in mind when broaching the subject
of vulvovaginal health.

HCP perspective on discussing
vulvovaginal health and role in improving
diagnosis and treatment
Few surveys investigate vulvovaginal health from the perspective of the HCP. In the HCP portion of the REVEAL
study, the survey responses of 602 HCPs (200 primary care
physicians, 202 obstetrician/gynecologists, and 200 nurse
practitioners) were compiled.6 Ninety-five percent of HCPs
thought that treating a woman’s vulvovaginal health was
important to her overall physical health, and most reported
that they discussed dyspareunia at least sometimes (36%
“often;” 49% “sometimes”).6 However, 44% of women who
experienced dyspareunia and spoke to an HCP said that they
initiated the conversation themselves; only 10% said that their
HCP initiated the conversation.6 Multiple factors may influence the degree to which HCPs discuss sexual topics with
patients, including lack of time, lack of training/experience,
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fear of embarrassing themselves or their patients, or even
personal religious beliefs.40

Discussion and practice
recommendations
The surveys described in this review reveal a large population
of menopausal women suffering in silence with VVA-related
symptoms that are significantly impacting their QoL, including their sexual relationships and self-esteem. In addition,
the surveys indicate that many of these women do not discuss their symptoms and that many lack information about
the possibility of effective treatment. Further research is
needed to examine the impact of VVA on partners of menopausal women and to explore outcomes, including sexual
functioning/satisfaction and QoL, for women whose VVA
has been treated. Future studies should also evaluate regional
differences in women’s expectations and experiences, such
as those that are related to their treatment options and the
health care system. The improved recognition, diagnosis,
and treatment of VVA depend on increased communication
between patients and HCPs regarding midlife vulvovaginal
changes and effective, well tolerated treatment options for
menopause-related vulvovaginal discomfort.
With improved health care, women are living longer in
the postmenopausal hypoestrogenic state. HCPs should communicate with their patients about the potential manifestations and management of VVA so that symptomatic women
may seek appropriate treatment rather than accepting pain
and discomfort as a natural consequence of aging. Because
many postmenopausal women, especially older women,
may no longer see an obstetrician/gynecologist regularly,
it is imperative to educate all clinicians, including those
in internal medicine, family physicians, and other primary
care providers, about the full impact of VVA and the need
to proactively and empathically address this condition. For
example, a diagnosis of VVA should be considered for
postmenopausal women who present to their primary care
physician with a history of recurrent UTIs or worsening
symptoms of urinary urgency.
HCPs may improve the diagnosis and treatment of VVA
by initiating conversations at routine examinations to increase
patient awareness and understanding of midlife vulvovaginal
changes and treatment options. Studies of the patient-HCP
dialogue have indicated that, in the case of potentially sensitive issues of sexuality, patients may not offer complaints
spontaneously, but will reveal them after being asked.41
Patients often prefer screening “ubiquity” statements that
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Table 3 Clinical findings indicating vulvovaginal atrophy
• Pale, smooth, shiny, or friable/unrugated epithelium
• Loss of elasticity of genital skin
• Vulvar dermatoses, lesions, or erythema
• Urethral caruncle or polyps
• Low serum estrogen levels
• Elevated vaginal pH $ 5.5
• Thinning of endometrial uterine lining
• Change in cytology of vaginal cells to primarily parabasal
and intermediate cells
Note: Data from43–45.

address the concerns of their group.21,42 An example of such
a statement would be, “Many women find after menopause
that they experience vaginal dryness, irritation, or pain during
sex. Have you experienced anything like that?” The HCP’s
use of focused questions that model the level of explicitness
desired from the patient can elicit more specific information.
HCPs can then use open-ended questions to follow up positive responses. In addition HCPs may schedule a follow-up
visit if additional time is required to address sexual issues.21
All HCPs who regularly see postmenopausal women have
a responsibility to their patients to routinely ask about
symptoms of VVA and to perform periodic clinical examinations to detect VVA (Table 3).43–45 In addition, providing
peri- and postmenopausal patients with at least one or two
information leads, such as pamphlets or reliable websites,
may motivate women to become better-informed advocates
of their own vulvovaginal health and to then seek treatment,
if necessary.
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